Inhibikase Therapeutics Inc (IKT) has a current Price-to-Book (P/B) ratio of 2.42. Compared to its 3-year average P/B ratio of -3.55, the current P/B ratio is approximately -168.15% higher. Relative to its 5-year average P/B ratio of -1.33, the current P/B ratio is about -281.10% higher. Inhibikase Therapeutics Inc (IKT) has a Forward Free Cash Flow (FCF) yield of approximately -9.61%. Compared to its 3-year average FCF yield of -104.64%, the current FCF yield is approximately -90.82% lower. Relative to its 5-year average FCF yield of -81.66%, the current FCF yield is about -88.23% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for IKT competitors is 11.49, providing a benchmark for relative valuation. Inhibikase Therapeutics Inc Corp (IKT.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of IKT increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of IKT in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is IKT currently overvalued or undervalued?

What is Inhibikase Therapeutics Inc (IKT) fair value?

IKT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Inhibikase Therapeutics Inc (IKT) is between NaN to NaN according to relative valuation method.

How does IKT's valuation metrics compare to the industry average?

The average P/S ratio for IKT's competitors is 11.49, providing a benchmark for relative valuation. Inhibikase Therapeutics Inc Corp (IKT) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Inhibikase Therapeutics Inc (IKT) as of Mar 03 2026?

As of Mar 03 2026, Inhibikase Therapeutics Inc (IKT) has a P/B ratio of 2.42. This indicates that the market values IKT at 2.42 times its book value.

What is the current FCF Yield for Inhibikase Therapeutics Inc (IKT) as of Mar 03 2026?

As of Mar 03 2026, Inhibikase Therapeutics Inc (IKT) has a FCF Yield of -9.61%. This means that for every dollar of Inhibikase Therapeutics Inc's market capitalization, the company generates -9.61 cents in free cash flow.

What is the current Forward P/E ratio for Inhibikase Therapeutics Inc (IKT) as of Mar 03 2026?

As of Mar 03 2026, Inhibikase Therapeutics Inc (IKT) has a Forward P/E ratio of -3.98. This means the market is willing to pay $-3.98 for every dollar of Inhibikase Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Inhibikase Therapeutics Inc (IKT) as of Mar 03 2026?

As of Mar 03 2026, Inhibikase Therapeutics Inc (IKT) has a Forward P/S ratio of 0.00. This means the market is valuing IKT at $0.00 for every dollar of expected revenue over the next 12 months.

IKT Valuation